Articles related to Urology

A narrative review of studies from 1974 to 2025 described testosterone activity across musculoskeletal, metabolic, cardiovascular, and neurological systems in women, with evidence strength varying by domain.

Older adults with advanced or metastatic urothelial carcinoma treated with enfortumab vedotin experienced substantially higher rates of severe toxicity and treatment discontinuation than younger patients, while survival outcomes appeared similar across age groups.

Researchers identified a transfer RNA, tRNA¹Arg(UCU), that appears to regulate androgen receptor dependence in prostate cancer. Preclinical studies suggest manipulating this pathway may influence treatment sensitivity and the development of drug-resistant disease states.

In patients with cisplatin-eligible muscle-invasive bladder cancer, perioperative enfortumab vedotin plus pembrolizumab improved event-free and overall survival compared with standard neoadjuvant gemcitabine-cisplatin chemotherapy in the phase 3 KEYNOTE-B15 trial.

The FDA granted Fast Track designation in September 2026 to multiple investigational oncology agents and one prostate cancer imaging strategy, highlighting continued regulatory support for therapies targeting high unmet needs across solid tumors and hematologic malignancies.

Researchers identified a previously unrecognized B7-H3-driven pathway that promotes immune suppression in castration-resistant prostate cancer. Preclinical findings suggest dual targeting of B7-H3 and MEK signaling altered the tumor microenvironment and improved antitumor activity in experimental models.